U.S., April 4 -- ClinicalTrials.gov registry received information related to the study (NCT06908772) titled 'Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients' on March 27.
Brief Summary: To evaluate the efficacy and safety of glumetinib combined with osimertinib as the first-line treatment for locally advanced or metastatic NSCLC.
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression
Intervention:
DRUG: Glumetinib Tablets
An ATP competitive, highly selective MET receptor tyrosine kinase inhibitor
DRUG: Osimertinib Mesylate Tablets
3rd EGFR-TKI
DRUG: Glumetinib Tab...